ClinicalTrials.gg

Myositis clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 215 studies for Myositis across more than 10 countries. 100 are recruiting or about to start. 61 of them are mainly about Myositis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13. Counting its 4 narrower conditions too, such as Dermatomyositis: 420 studies, 159 open.

Status

Recruiting
71
Completed
60
Not yet recruiting
23
Status unknown
20
Active, not recruiting
14
Terminated
10

Phase

Phase 2
49
Phase 1
45
Early Phase 1
20
Phase 3
18
Phase 4
9

Where

United States
78
China
54
France
40
United Kingdom
22
Germany
21
Spain
18

Who develops what

Add Myositis to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 30 programs from 24 companies, 6 with this as their studies’ main aim; 2 with a live phase 3 study; 1 primary completion in the next 12 months. Compare Bristol-Myers Squibb, AstraZeneca and Boehringer Ingelheim here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
fludarabineRecent, limitedPhase 4 trial recorded
Evidence
  • NCT06733935 · Nkarta, Inc. · Phase 2 · live · background · “Fludarabine” · registered Dec 2024
Beijing Biotech18% of its industry studies11 study
CyclophosphamideRecent, limited
Evidence
  • NCT06733935 · Nkarta, Inc. · Phase 2 · live · background · “Cyclophosphamide” · registered Dec 2024
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed11 study
GlucocorticoidsRecent, limited
Evidence
  • NCT05379634 · Johnson & Johnson · Phase 2 · background · “Glucocorticoids” · registered May 2022
Staidson (Beijing) Biopharmaceuticals Co., Ltd33% of its industry studies11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
nerandomilastApproved: US 2025 · EU 2026☆ Track1 live phase-3 study: NCT07789015Boehringer Ingelheim

The 1 in phase 3 with the nearest primary completion, of 30 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2027 est.Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes · Cartesian Therapeutics · Phase 2 main aimNCT07391605 Descartes-08 in Autoantibody Myositis — primary endpoint: Major improvement of 2016 ACR/EULAR Total Improvement score · 60 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Myositis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 1 open · JAK inhibitors 1 open

Coming up

32studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 71 Myositis studies recruiting now, 27 (38%) set no upper age limit and 36 (51%) stop at 75 or younger. 7 (10%) take children under 18. 0 (0%) are for women only and 1 (1%) for men only; 9 (13%) take healthy volunteers.

Recruiting studies that take each age, of 71
AgeWomenMen
105 (7%)5 (7%)
1867 (94%)67 (94%)
3069 (97%)69 (97%)
4069 (97%)69 (97%)
5070 (99%)71 (100%)
6567 (94%)68 (96%)
7543 (61%)44 (62%)
8531 (44%)32 (45%)

Across all 215 studies, recruiting or not: 33% stop at 75 or younger and 13% at 65; 15% take children; <1% are for women only and <1% for men only; 16% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Myositis studies take

Of 19 interventional studies with no phase under Myositis, half reached primary completion within 23 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Interventional, no phase23 mo12–51 · 19 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Started recruiting1

Studies

Recruiting first, then most recently updated. Showing 50 of 215. Browse all 215 → or search them.